Ascendis Pharma A/S (ASND) Stock: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$238.90
4.57 (1.95%)
â˛
5d:
+5.24%
30d:
+0.56%
90d:
-5.45%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ASND is fairly priced but lacks strong directional signals. At -5.8% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ASND is fairly priced but lacks strong directional signals. At -5.8% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$134.37
Based on -10.4% avg growth
INTRINSIC VALUE TODAY
$83.43
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $238.90, which is considered fair relative to its 30-day fair value range of $221.91 to $245.38. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.8) compared to its historical average (29.7). Remarkably, the market is currently pricing in an annual earnings decline of 5.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is showing sideways momentum. The price is approaching resistance at $240.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $307.62 (+28.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ASND is showing sideways momentum. The price is approaching resistance at $240.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $307.62 (+28.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$221.91 -
$245.38
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.8% below Wall St target ($307.62)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$221.91 -
$245.38
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$219.52
Resistance Level
$240.21
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.84
Wall Street Target
$307.62
(+28.8%)
Revenue Growth (YoY)
114.7%
Profit Margin
70.9%
Valuation Discount vs History
-5.8% cheaper
PE vs Historical
24.8 vs 29.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.8%
(market-implied from PE analysis)
1-Year Target
$225.04
(-6%)
2-Year Target
$211.99
(-11%)
3-Year Target
$199.70
(-16%)
3-Yr Target (if PE normalizes)
(PE: 25â30)
$238.73
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.8, Growth: -24.8%)
$174.16
(+-27%)
Base:
(SPY PE: 19.9, Growth: -24.8%)
$139.22
(-42%)
Bear:
(PE: 16.9, Growth: -24.8%)
$118.34
(-51%)
đ
Valuation based on Current Earnings
Trailing PE: 17.63 | Current EPS (TTM): $13.29
Bull Case
$186.51
(-22%)
Analyst growth -27.6%, PE expands to 19.4
Base Case
$169.55
(-29%)
Market implied -27.6%, PE stable at 17.6
Bear Case
$159.34
(-33%)
Severe decline -20.0%, PE contracts to 15.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.8 to 29.7
Stabilization Target:
$285.60
(+19.5%)
PE Expansion Potential:
+19.5%
Share & Embed Analysis
Last updated: October 21, 2026 8:25 PM ET
Data refreshes hourly during market hours. Next update: 9:25 PM
Data refreshes hourly during market hours. Next update: 9:25 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 60 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 62 BUY |
